Patents Examined by Misook Yu
  • Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals
    Patent number: 9023350
    Abstract: A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: May 5, 2015
    Assignee: Association Civil de Estudios Superiores
    Inventor: Juan Eduardo María Gallo Barraco
  • RNA-guided human genome engineering
    Patent number: 9023649
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: May 5, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Prashant G. Mali, George M. Church, Luhan Yang
  • Identification, assessment, and therapy of cancers with innate or acquired resistance to ALK inhibitors
    Patent number: 9018230
    Abstract: Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) positive for ALK mutations are likely to respond to treatment with an ALK inhibitor and/or whether a patient having such cancer(s) is likely to have a relatively slower disease progression. Further described are methods for prognosing a time course of disease in a subject having such cancer.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: April 28, 2015
    Assignee: Jichi Medical University
    Inventors: Hiroyuki Mano, Young L. Choi, Manabu Soda
  • Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
    Patent number: 9017660
    Abstract: This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: April 28, 2015
    Assignees: Advaxis, Inc., The Trustees of the University of Pennsylvania
    Inventors: Vafa Shahabi, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew Seavey
  • Inhibitors of her3 activity
    Patent number: 9011851
    Abstract: The present invention relates to a pharmaceutical composition comprising as an active agent an inhibitor of HER3 activity, particularly an anti-HER3-antibody. Further, the use of this composition for the diagnosis, prevention or treatment of hyperproliferative diseases, particularly tumor diseases is disclosed.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: April 21, 2015
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Edward Htun-Van Der Horst
  • Prevention of bacterial contamination
    Patent number: 8999365
    Abstract: A compound of formula I: wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, the sum of the carbon atoms in the groups R1 and R2 being at least 10 and preferably 10 to 20, is used to prevent biofilm formation on a surface. The compounds are particularly useful as coatings or treatments for medical devices, including stents, catheters and wire guides.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: April 7, 2015
    Assignee: Sinclair Pharmaceuticals Limited
    Inventors: Jonathan Lane, Olof Torgny Sjodin
  • PODXL protein in colorectal cancer
    Patent number: 8999656
    Abstract: The present disclosure provides a method for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of PODXL protein in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount; b) comparing said sample value from step a) with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to said second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to said first group. Related uses, means and a method of treatment are also provided.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: April 7, 2015
    Assignee: Atlas Antibodies AB
    Inventors: Karin Jirström, Mathias Uhlén, Fredrik Pontén
  • Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
    Patent number: 8940300
    Abstract: The present invention relates to humanized antibodies that specifically bind an EC1 domain of a mammalian Cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating Cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention. Cadherin-11-mediated disorders suitable for treatment by the methods of the invention include inflammatory disorders (e.g., inflammatory joint disorders, such as rheumatoid arthritis), fibrosis and cancer.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: January 27, 2015
    Assignee: Adheron Therapeutics, Inc.
    Inventor: James G. McArthur
  • Methods for treating breast cancer
    Patent number: 8900588
    Abstract: The present disclosure is directed to methods of treating and preventing breast cancer or recurrence of breast cancer with compositions comprising anti-progastrin antibodies.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: December 2, 2014
    Assignees: Les Laboratories Servier, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jean-François Floch, Leïla Houhou, Françoise Cailler, Dominique Joubert, Frédéric Hollande
  • Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same
    Patent number: 8901280
    Abstract: The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: December 2, 2014
    Assignee: Gene Techno Science Co., Ltd.
    Inventors: Shigeyuki Kon, Chiemi Kimura, Toshimitsu Uede
  • Humanized antibodies with anti-tumor activity
    Patent number: 8901279
    Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: December 2, 2014
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard
  • Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
    Patent number: 8883162
    Abstract: The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) complex. Preferably, the DNL™ complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-?2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: November 11, 2014
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • B cell surface reactive antibodies
    Patent number: 8877199
    Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: November 4, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak
  • Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
    Patent number: 8877204
    Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: November 4, 2014
    Assignee: University of Connecticut Health Center
    Inventors: Pramod K. Srivastava, Robert J. Binder
  • Stimulation of an immune response by cationic lipids
    Patent number: 8877206
    Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: November 4, 2014
    Assignee: PDS Biotechnology Corporation
    Inventors: Weihsu Chen, Weili Yan, Kenya Toney, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • IL-1 binding proteins
    Patent number: 8841417
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: September 23, 2014
    Assignee: ABBVIE Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • Methods for producing active scFv antibodies and libraries therefor
    Patent number: 8841238
    Abstract: The present disclosure describes scFv antibody libraries, antibodies isolated from the libraries, and methods of producing and using the same.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: September 23, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite de Strasbourg
    Inventors: Pierre Emile Ulysse Martineau, Etienne Weiss
  • IL-17 binding proteins
    Patent number: 8835610
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: September 16, 2014
    Assignee: Abbvie Inc.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers
  • Methods for identification of sites for IgG conjugation
    Patent number: 8834885
    Abstract: The present disclosure relates to immunoglobulins and immunoglobulin conjugates with reduced oligomerization and efficient labeling and compositions, methods of generating such immunoglobulins and immunoglobulin conjugates and methods of using such immunoglobulin conjugates particularly in the treatment and prevention of disease.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: September 16, 2014
    Assignees: Novartis AG, Massachusetts Institute of Technology
    Inventors: Naresh Chennamsetty, Bernhard Helk, Veysel Kayser, Bernhardt Trout, Vladimir Voynov
  • Peptides and aptamers thereof as specific modulators of mutant p53 function
    Patent number: 8822420
    Abstract: In the present application isolated peptides and aptamers thereof able to interact with structural and conformational p53 mutants within the region of the wild-type p53 DNA binding core domain comprised from amino acids 74 to amino acids 298 using the yeast two-hybrid method are disclosed. These PAs are able to efficiently recognize several different p53 point mutants but not wild-type p53. Therefore the peptides and aptamers identified can be useful as inhibitors of mutant p53-associated pro-oncogenic functions for anticancer therapy or as diagnostic tools for mut-p53 or wild-type p53 or as template for designing new peptido-mimetic drugs able to specifically target tumor cells.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: September 2, 2014
    Assignee: Universita Degli Studi di Trieste
    Inventors: Giannino Del Sal, Elisa Guida, Andrea Bisso